SCHEMBL14619875

SCHEMBL14619875

O=C(O)c1cc(CBr)ccc1-c1c2ccc(=O)cc-2oc2cc(O)ccc12

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 3/20 0.72
▸ L3MBTL1 Q9Y468 1/20 0.72
▸ MEN1 O00255 2/20 0.60
▸ POLB P06746 2/20 0.60
▸ KMT2A Q03164 2/20 0.60
▸ ALPL P05186 1/20 0.60
▸ ALPI P09923 1/20 0.60
▸ ALPG P10696 1/20 0.60
▸ ATM Q13315 1/20 0.58
▸ PLEC Q15149 1/20 0.58
▸ CA9 Q16790 14/20 0.57
▸ CA1 P00915 12/20 0.57
▸ CA2 P00918 12/20 0.57
▸ CA12 O43570 4/20 0.57
▸ CA14 Q9ULX7 3/20 0.57
▸ CA7 P43166 3/20 0.55
▸ ESR1 P03372 1/20 0.55
▸ DNASE1L3 Q13609 1/20 0.54
▸ PRMT1 Q99873 1/20 0.54
▸ ALB P02768 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13369020 0.89 USP2 (0.75) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL10060092 0.89 USP2 (0.72) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL20056705 0.88 USP2 (0.69) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL18383481 0.87 USP2 (0.68) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL29668458 0.87 USP2 (0.68) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL23318855 0.85 USP2 (0.66) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL1437042 0.84 USP2 (0.78) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL20254033 0.84 USP2 (0.77) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL24274756 0.84 USP2 (0.64) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL10098714 0.84 USP2 (0.76) USP2L3MBTL1MEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220009956-A1 PREPARATION OF OLIGO CONJUGATES EMERALD THERAPEUTICS INC (US) 2022-01-13 — — US disclosed
US-20160333045-A1 Preparation of Oligo Conjugates Emerald Therapeutics, Inc. 2016-11-17 — — US disclosed
US-20160333045-A1 Preparation of Oligo Conjugates Emerald Therapeutics, Inc. 2016-11-17 — — US disclosed
US-9289502-B2 Preparation of oligo conjugates Emerald Therapeutics, Inc. (US) 2016-03-22 — — US disclosed
US-9289502-B2 Preparation of oligo conjugates Emerald Therapeutics, Inc. (US) 2016-03-22 — — US disclosed
US-20140256911-A1 PREPARATION OF OLIGO CONJUGATES Emerald Therapeutics, Inc. 2014-09-11 — — US disclosed
US-20140256911-A1 PREPARATION OF OLIGO CONJUGATES Emerald Therapeutics, Inc. 2014-09-11 — — US disclosed
US-7160735-B2 Tagged microparticle compositions and methods MONOGRAM BIOSCIENCES, INC. (US) 2007-01-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160333045-A1 Preparation of Oligo Conjugates OSTC, PCBP1, PAICS USP2 2255/4885L3MBTL1 2596/4885MEN1 3671/4885
US-20220009956-A1 PREPARATION OF OLIGO CONJUGATES OSTC, PCBP1, PAICS USP2 2255/4885L3MBTL1 2596/4885MEN1 3671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback